These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 2870577)
21. Active specific immunotherapy of established micrometastases with BCG plus tumor cell vaccines: effective treatment of BCG side effects with isoniazid. Hanna MG; Pollack VA; Peters LC; Hoover HC Cancer; 1982 Feb; 49(4):659-64. PubMed ID: 7055781 [TBL] [Abstract][Full Text] [Related]
22. Intratumoral BCG therapy of transplanted head and neck tumors in strain 2 guinea pigs. Bier J; Bier H; Kleinschuster S; Rapp H Head Neck Surg; 1982; 4(6):457-67. PubMed ID: 7118547 [TBL] [Abstract][Full Text] [Related]
23. Major histocompatibility complex class II antigen expression during potentiation of line-10 tumor immunity after intralesional administration of bacillus Calmette-Guérin. Steerenberg PA; De Jong WH; Geerse E; Aleva BJ; Besselink CM; Van Rens BT; Rutten VP; Poels LG; Scheper RJ; Den Otter W Cancer Immunol Immunother; 1990; 32(2):95-104. PubMed ID: 1963114 [TBL] [Abstract][Full Text] [Related]
24. The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. II. Establishment of tumor-specific immunotherapy models utilizing MDP hapten-reactive helper T cell activity. Sano H; Kosugi A; Sano S; Fujiwara H; Hamaoka T Cancer Immunol Immunother; 1987; 25(3):180-4. PubMed ID: 2960447 [TBL] [Abstract][Full Text] [Related]
25. Influence of type of oil and surfactant concentration on the efficacy of emulsified Mycobacterium bovis BCG cell walls to induce tumor regression in guinea pigs. Yarkoni E; Rapp HJ Infect Immun; 1980 Jun; 28(3):881-6. PubMed ID: 6995325 [TBL] [Abstract][Full Text] [Related]
26. Regression of established intradermal tumors and lymph node metastases in guinea pigs after systemic transfer of immune lymphoid cells. Smith HG; Harmel RP; Hanna MG; Zwilling BS; Zbar B; Rapp HJ J Natl Cancer Inst; 1977 May; 58(5):1315-22. PubMed ID: 853526 [TBL] [Abstract][Full Text] [Related]
27. Major histocompatibility complex class II antigen expression on leucocyte subpopulations in the draining lymph node and tumour in the early phase of bacillus-Calmette-Guérin-induced tumour regression. Steerenberg PA; De Jong WH; Geerse E; De Graaf A; Scheper RJ; Den Otter W; Ruitenberg EJ Cancer Immunol Immunother; 1991; 33(3):189-97. PubMed ID: 1828389 [TBL] [Abstract][Full Text] [Related]
28. Suppression and regression of a transplanted tumor in the guinea pig colon mediated by Mycobacterium bovis, strain BCG. Harmel RP; Zbar B; Rapp HJ J Natl Cancer Inst; 1975 Feb; 54(2):515-7. PubMed ID: 234537 [TBL] [Abstract][Full Text] [Related]
29. Experimental screening of BCG preparations produced for cancer immunotherapy: safety and immunostimulating and antitumor activity of four consecutively produced batches. de Jong WH; Steerenberg PA; Kreeftenberg JG; Tiesjema RH; Kruizinga W; van Noorle Jansen LM; Ruitenberg EJ Cancer Immunol Immunother; 1984; 17(1):18-27. PubMed ID: 6563941 [TBL] [Abstract][Full Text] [Related]
30. Antitumor activity of bacterial infection. II. effect of Listeria monocytogenes on growth of a guinea pig hepatoma. Bast RC; Zbar B; Miller TE; Mackaness GB; Rapp HJ J Natl Cancer Inst; 1975 Mar; 54(3):757-61. PubMed ID: 164568 [TBL] [Abstract][Full Text] [Related]
31. Experimental cancer immunotherapy: comparison of tumor rejection if F344 rats given live Mycobacterium bovis (Strain BCG) and killed Corynebacterium parvum. Likhite VV J Natl Cancer Inst; 1976 May; 56(5):985-9. PubMed ID: 994209 [TBL] [Abstract][Full Text] [Related]
32. Long term protection in bladder cancer following intralesional immunotherapy. Reichert DF; Lamm DL J Urol; 1984 Sep; 132(3):570-3. PubMed ID: 6381762 [TBL] [Abstract][Full Text] [Related]
33. Prevention of tumor growth after intradermal injection of BCG extracts: a comparison of results in strain-2 guinea pigs from the National Institutes of Health and from the National Jewish Hospital and Research Center. Zbar B; Minden P; McClatchy JK; Rapp HJ J Natl Cancer Inst; 1976 Feb; 56(2):443-4. PubMed ID: 176390 [TBL] [Abstract][Full Text] [Related]
34. Mechanism of BCG induced regression of line 10 hepatocarcinoma in the guinea pig. Steerenberg PA; De Jong WH; Ruitenberg EJ In Vivo; 1991; 5(6):655-61. PubMed ID: 1810452 [TBL] [Abstract][Full Text] [Related]
35. Adoptive immunity to the guinea pig line 10 hepatoma and the nature of in vitro lymphoid-tumor cell interactions. Shu S; Steerenberg PA; Hunter JT; Evans CH; Rapp HJ Cancer Res; 1981 Sep; 41(9 Pt 1):3499-506. PubMed ID: 7260913 [TBL] [Abstract][Full Text] [Related]
36. Tumor regression and induction of anti-tumor immunity by local chemotherapy of guinea-pigs bearing a line-10 hepatocarcinoma. Claessen AM; Valster H; Bril H; Steerenberg PA; Tan BT; Scheper RJ Int J Cancer; 1991 Feb; 47(4):626-32. PubMed ID: 1995491 [TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of living BCG or BCG cell walls (CW) in the treatment of guinea pig hepatoma. Zbar B; Hunter J; Rapp HJ; Canti G Cancer; 1979 Feb; 43(2):484-91. PubMed ID: 421175 [TBL] [Abstract][Full Text] [Related]
38. Active specific immunotherapy of established micrometastasis: effect of cryopreservation procedures on tumor cell immunogenicity in guinea pigs. Peters LC; Hanna MG J Natl Cancer Inst; 1980 Jun; 64(6):1521-5. PubMed ID: 6990075 [TBL] [Abstract][Full Text] [Related]
39. Complete regression of a guinea pig hepatocarcinoma by immunotherapy with "tumor-immune" RNA or antibody to fibrin fragment E. Schlager SI; Dray S Isr J Med Sci; 1976; 12(4-5):344-59. PubMed ID: 181352 [TBL] [Abstract][Full Text] [Related]
40. Histopathology of tumor regression after intralesional injection of Mycobacterium bovis. IV. Development of immunity to tumor cells and BCG. Hanna MG; Snodgrass MJ; Zbar B; Rapp HJ J Natl Cancer Inst; 1973 Dec; 51(6):1897-908. PubMed ID: 4358147 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]